- Home
- OPFI vs MRVI Comparison
OPFI vs MRVI Comparison
Compare OPFI & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- MRVI
- Stock Information
- Founded
- OPFI 2009
- MRVI 2014
- Country
- OPFI United States
- MRVI United States
- Employees
- OPFI N/A
- MRVI 560
- Industry
- OPFI Finance: Consumer Services
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- MRVI Health Care
- Exchange
- OPFI Nasdaq
- MRVI Nasdaq
- Market Cap
- OPFI 300.3M
- MRVI 350.1M
- IPO Year
- OPFI N/A
- MRVI 2020
- Fundamental
- Price
- OPFI $10.17
- MRVI $2.42
- Analyst Decision
- OPFI Buy
- MRVI Hold
- Analyst Count
- OPFI 2
- MRVI 10
- Target Price
- OPFI $11.75
- MRVI $5.84
- AVG Volume (30 Days)
- OPFI 1.3M
- MRVI 1.5M
- Earning Date
- OPFI 08-06-2025
- MRVI 08-11-2025
- Dividend Yield
- OPFI 9.79%
- MRVI N/A
- EPS Growth
- OPFI N/A
- MRVI N/A
- EPS
- OPFI N/A
- MRVI N/A
- Revenue
- OPFI $320,831,000.00
- MRVI $219,830,000.00
- Revenue This Year
- OPFI $116.69
- MRVI N/A
- Revenue Next Year
- OPFI $9.90
- MRVI $7.23
- P/E Ratio
- OPFI N/A
- MRVI N/A
- Revenue Growth
- OPFI 31.26
- MRVI N/A
- 52 Week Low
- OPFI $3.93
- MRVI $1.67
- 52 Week High
- OPFI $17.73
- MRVI $9.60
- Technical
- Relative Strength Index (RSI)
- OPFI 46.36
- MRVI 49.60
- Support Level
- OPFI $10.11
- MRVI $2.28
- Resistance Level
- OPFI $10.76
- MRVI $2.47
- Average True Range (ATR)
- OPFI 0.47
- MRVI 0.14
- MACD
- OPFI 0.08
- MRVI -0.01
- Stochastic Oscillator
- OPFI 51.49
- MRVI 27.45
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.